HAPPY HOLIDAYS — SURPRISE!
⠀
Hd.muscle has extended their 12 days of Holiday sales SITE WIDE.
⠀
You can now stock up on multiple HD products ALL on sale NOW before they sell out!!!!
⠀
Everything is 10-25% off on our .COM, .CA and .EU webstore.
⠀
SALE ends January 6th.
⠀
BUT SAVE an ADDITIONAL 10% when you use my code:
⠀
⠀
⠀
Thank you to assuage for sending me over a new seat protector!
This is a great gift for any one who is traveling during this unprecedented time!
This ultra cozy seat protector is an affordable way to make sure you are protected from germs.
I am not doing any traveling right now but I will definitely be using it when I do. Especially flying.
It is designed to fit most seats as well!
We wanted to make sure the Ultra Cozy is made out of a material that can be easily and effectively machine washed. Laundering garments can be a simple and powerful way to limit the spread of Covid-19.
And if you dont like blue it also comes in pink!
I was recently sent two Tru47 Masks and also their moisture rich soap and hand and body lotion.
Tru47:
What’s upfront is what we stand for. TRU47® is a company founded on integrity, dedicated to quality and motivated by the real deal, staying TRU to our nature in everything we do.
The 47 in our name honors one of nature’s most noble elements, silver, known in scientific circles as Ag47, and renowned for its naturally effective antibacterial properties. From spritzes and sprays to Stellarcleenz wipes and wraps, our family of products are inspired with your health in mind. And silver is the common thread that weaves them all together.
TRU47® Putting the power of nature’s first true antimicrobial to work for you.
First impression of the masks is that they are light weight. But after wearing them for a few days my favourite part about them is how breathable they are! They are so much better than most masks for breathing! I absolutely love that!
They are also antimacrobial which is amazing!
The two masks that they sent me are:
You can find out more about the masks via their site:
For me they are a 10/10 based on all of the masks I have tried. They would be my first recommendation.
About the brand:
All TRU47 offerings are made of the highest quality 99.99% pure ionically bathed silver, plated on to superior ripstop nylon. (It is not the inferior coated particle process known as nanotechnology).
Silver is scientifically proven to be a powerful anti-microbial. Innovative new styles additionally feature 99.99% pure Copper outer layers Copper is a known anti-viral deterrent, providing an extra layer preferable by some in highly populated environments.
Each TRU47 silver face mask is not N95, medical, or surgical coverings. Further, they are not CDC approved to protect against COVID-19 virus. Rather, they are designed with care and style to provide face coverage while inside or outdoors when social distancing.
All are detailed for comfortable wear and are breathable making them useable for longer wear. A core benefit is that every style is re-useable without washing repeatedly, making them very cost-effective and environmentally thoughtful.
Merry Christmas and Happy Holidays!
First off I just want to thank everyone for your support this year! I truly appreciate each and every one of you!
This blog is something I have been doing for years - I plan on shifting gears here. Lately I have been posting mostly press releases but I want to share more.
With that being said I am going to go back to my blogging roots. I will be not only posting press releases but I will be doing:
Reviews
Prep Updates
Competition Tips
Nutrition Advice
And more updates about me and competing (a log if you may).
Also a reminder about my links and codes:
My newsletter: https://trainitright.us13.list-manage.com/subscribe/post?u=d5a623a7a8431f5470b4dbace&id=e0f6635e90
Shoulder guide 20$ flash sale is currently going on!
https://mailchi.mp/38dd05a0181d/embracethesuck
My podcast
https://podcasts.apple.com/ca/podcast/the-train-it-right-life/id1516726326
Affiliate links
I do make a small commission if you shop the following products.
All codes: Trainitright
Except
Coffee over cardio - 10trainitright
http://coffeeovercardio.com/discount/10TRAINITRIGHTb
Pro Tan
Code: trainitright
20$ shoulder guide: shoulder guide
HD MUSCLE
Pure
https://shop.puremuscleandfitness.com/?aff=trainitright
Performa
https://www.performa.com/?aff=148
The shoe fairy
https://shoefairyofficial.com/?ref=TRAINITRIGHT
Ironbull strength
Preparing for COVID-19 Vaccine
EDMONTON, AB, Dec. 22, 2020 /CNW/ - Alberta's community pharmacists have provided over 1 Million flu shots in less than eight weeks while at the same time instituting COVID-19 protocols into their practices. Pharmacists have become the primary immunizers in the province, having provided 78% of all flu shots this year. When refrigerator stable COVID-19 vaccines become available, pharmacists will be well prepared to meet the vaccination expectations of the province's 4.5 Million people.
Community pharmacists have a proven, robust, and safe vaccine program for public health vaccination. Since 2009, Alberta pharmacists have participated in the Influenza Immunization Program by offering publicly funded vaccination, close to peoples' homes, in over 1500 pharmacies across the province. Alberta is the national leader for pharmacist administered vaccines.
This year, in an effort to mitigate a potential twin-demic, one of both circulating influenza and COVID-19 virus, over 4600 community pharmacists went to work to ensure the public would receive their flu shot in a timely manner. Pharmacists implemented measures to ensure appropriate physical distancing, masking, and hand-hygiene, as well as investments in infrastructure to support symptom screening and appointment scheduling using online virtual care systems. Consequently, Alberta has yet to identify a single lab-confirmed case of influenza in the province.
Community pharmacists recognize that early vaccine products, such as the Pfizer vaccine, have storage and mobility requirements that limit this vaccine to being administered at Alberta Health Services facilities. However, there are additional vaccine candidates with better stability at refrigerator temperatures awaiting approval by Health Canada. These are ideal for use by Alberta's existing community pharmacy infrastructure for broad distribution.
In the interim, community pharmacists continue to meet their patients' healthcare needs in-person and using virtual care technologies. With vaccines beginning to arrive in the province, many people are turning to their pharmacist as their trusted source for information about COVID-19 vaccine. When COVID-19 vaccine becomes available in pharmacies, community pharmacists are well prepared to:
Alberta's pharmacists continue to support their patients in their communities during the pandemic. The Alberta Pharmacists' Association is committed to ensuring that all community pharmacists will be able to offer COVID-19 vaccination, regardless of corporate affiliation, in a way that benefits every Albertan across the province.
For two decades, the Alberta Pharmacists' Association (RxA) has been a champion for pharmacists in Alberta. We play an integral role in expanding pharmacists' practice, and we continue to advocate on their behalf towards excellence in patient care.
SOURCE Alberta Pharmacists' Association
Gym-related injuries are extremely common. Every year, thousands of people hurt their back while working out. To overcome the pain, they are forced to make a few lifestyle changes. Here are some tips on how to straighten out your spine.
Contrary to common belief, an extremely soft mattress doesn’t have any long-term health benefits. After sustaining a back injury, you need a firm mattress that fully supports your spine. Over time, you’ll should gradually begin to experience less pain. It’s also important to sleep in an ideal position at night. Most experts suggest sleeping on your side with your hips and knees bent. This helps further reduce the amount of stress placed upon your spine.
You should make stretching a part of your daily routine. When sitting or lying in one spot for long periods of time, the spine can stiffen up. This increases the likelihood of you experiencing discomfort. Your body naturally craves movement. Upon waking up in the morning, develop a habit of doing a few light stretches. Some of the simplest activities including shoulder rolls, overhead stretches, and pelvic lifts.
While there are some at-home treatments that can help straighten your spine, nothing beats being able to be evaluated by a licensed professional. An experienced physician can quickly determine the specific source of your trouble. After you’ve been examined and X-rayed, the doctor may suggest minimally invasive spine surgery. Because the surrounding tissues and muscles won’t be impacted, your recovery will be a lot quicker.
Nutrition plays a major role in keeping your spine strong. Vitamin D is extremely critical. While sunlight naturally triggers the body to produce vitamin D, most people aren’t outdoors as much during the winter. This means they may need to take a daily vitamin D supplement. Calcium is just important. Among the foods rich in the mineral include kale, spinach, sardines, mild, and cheese. Boron and magnesium are two other minerals that people tend to lack in their diet.
Footwear can have a big impact on spine health. Always may sure your shoes are supportive and properly fitted. Studies have shown that flip-flops and high heels tend to unnecessary pressure on the back. It’s also important to throw away your athletic shoes after they’ve gotten old.
When your back begins to experience pain, never wait to take action. Your spine impacts your ability to move freely. Attempting to fight through the discomfort will only make things worse.
TORONTO, Dec. 23, 2020 /CNW/ - Getting a COVID-19 vaccination will be one of the most important and effective things Ontarians can do to stop the pandemic once vaccines become widely available. Ontario's doctors are sharing their expert advice to ensure Ontarians have the information they need to keep their families safe and healthy.
Here are the Top 10 COVID-19 Vaccine Questions and Answers:
Should I get the vaccine? Yes. Ontario's doctors trust this vaccine because it works well and I safe so we encourage the public to receive the vaccine when they are able to. Protect yourself and protect others. Ask your doctor to learn more.
If you would like to learn more about the COVID-19 vaccine, Ontario's doctors will be releasing a series of videos from its expert panel on Facebook, Twitter and Instagram. To learn more about the COVID-19 vaccine, visit AskOntarioDoctors.ca.
About the OMA
The Ontario Medical Association represents Ontario's 43,000-plus physicians, medical students and retired physicians, advocating for and supporting doctors while strengthening the leadership role of doctors in caring for patients. Our vision is to be the trusted voice in transforming Ontario's health-care system.
SOURCE Ontario Medical Association
Health Professionals Petition CDC for Guidance: Americans Use Nasal Sprays to Combat COVID-19 Pandemic; Doctors Use in Treating Patients
“Studies show nasal spray use reduces risk of COVID-19 transmission and infection”
(Washington, DC)—Today, a consortium of 15 doctors, nurses and other public health professionals petitioned the Centers for Disease Control to issue Guidance calling on: Americans to use nasal sprays to combat the COVID-19 pandemic; and doctors to use them in treating COVID-19 patients.
The petition has also been placed on Change.org and the medical professionals are seeking support for it from all Americans: https://www.change.org/cdcguidance
The petition in particular calls on CDC to tell Americans to use nasal sprays as part of a layered defense against COVID-19. “You wash your hands; you should wash your nose, too. You wear a mask and social distance; you should do that and use a nasal spray,” said Dr. Alonzo Jones, one of the petitioners, and an inventor of one of the studied nasal sprays.
“In fact, we have more data supporting the use of nasal sprays against COVID-19 than we had supporting the use of masks and social distancing when CDC told Americans to do those things,” Dr. Mark Cannon, another petitioner, said. “These nasal sprays are inexpensive, non-invasive, safe, easy to use and you can get them off-the-shelf at your local store. It’s pure commonsense,” Cannon added.
“We have data showing that certain nasal sprays don’t just wash away the virus. Certain sprays actually block, deactivate and/or kill the virus,” said Dr. Gustavo Ferrer, a respiratory illness expert who has conducted research on the use of nasal sprays to combat COVID-19, and is among the petitioners.
As a result, the petition calls specifically for CDC Guidance to focus on the use of nasal sprays that contain Xylitol and grapefruit seed extract. Recent studies have found that these natural components used together are antiviral (they block SARS-CoV-2 adhesion to the nasal membrane) and virucidal (they kill or deactivate the virus). One such spray, Xlear, is currently widely available in the US. Xlear has been used by millions of people worldwide, over twenty-plus years, without any adverse effects reported.
Additionally, a new, small clinical study found Xlear lessens the severity and shortens the duration of COVID-19 illnesses, and reduces the risk of further transmission, which is why the petition calls for guidance to doctors to use it as an adjunct to current treatments.
It has been a hot minute! Sorry for my absence! But Im back! Heres a short episode about life, where I have been, covid lockdowns and staying on track during this tough time.
Podcast: Play in new window | Download
Subscribe: RSS
Data show DARZALEX® in combination with bortezomib, thalidomide and dexamethasone (VTd) before and after autologous stem cell transplant improved response rates and progression-free survival compared to VTd alone
TORONTO, Dec 22, 2020 /CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announce that Health Canada has approved DARZALEX® (daratumumab) in combination with bortezomib, thalidomide and dexamethasone (VTd) for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT).1 This represents the first Canadian approval of a biologic for newly diagnosed patients who are eligible for a stem cell transplant and it is the fifth approval for DARZALEX®.
The approval is based on results from the Phase 3 CASSIOPEIA (MMY3006) study that demonstrated the addition of DARZALEX® to VTd before and after ASCT resulted in deeper responses, as indicated by the higher stringent complete response (sCR) rate, and improved progression-free survival (PFS) compared to VTd alone.2
"This important Phase 3 clinical study is robust in terms of design, number of participating patients and efficacy results," said Dr. Richard LeBlanc, hematologist and Myeloma Canada Chair on multiple myeloma at Université de Montréal. "This study evaluated the impact of adding daratumumab before and after autologous stem cell transplantation in first line treatment and showed that the addition of daratumumab significantly reduces the risk of progression from multiple myeloma and death."
Data from the study were first presented at the 2019 American Society of Clinical Oncology Annual Meeting and simultaneously published in The Lancet.10
Results showed that the primary endpoint of sCR rate post-transplant was significantly higher in the DARZALEX®-VTd arm compared to VTd alone (29 per cent vs. 20 per cent; p-value=0.0010).3 The addition of DARZALEX® to VTd at a median follow-up of 18.8 months resulted in a 53 per cent reduction in the risk of disease progression or death compared to VTd alone
(Hazard Ratio [HR] = 0.47; 95 per cent CI, 0.33–0.67; P<0.0001).4
"The DARZALEX clinical development program has led to many important firsts, but more importantly, it has generated key insights and understanding into the biology and treatment of multiple myeloma," said Craig Tendler, M.D., Vice President, Late Development and Global Medical Affairs, Oncology, Janssen Research & Development, LLC. "This milestone marks the first approval of a biologic in Canada for newly diagnosed, transplant-eligible patients and it is the fifth Canadian approval for DARZALEX®. Yet our work is far from over, as we are committed to discovering and developing innovative treatments like DARZALEX® for the benefit of patients facing a multiple myeloma diagnosis."
About the CASSIOPEIA Study
This randomized, open-label, multicenter, Phase 3 study is sponsored by the French Intergroupe Francophone du Myelome (IFM) in collaboration with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Research & Development, LLC.5
The study included 1,085 newly diagnosed patients with previously untreated, symptomatic multiple myeloma who were eligible for high-dose chemotherapy and stem cell transplant (median age is 58).6 In the first part of the study, patients were randomized to receive induction treatment with VTd alone or in combination with DARZALEX®, high-dose therapy and ASCT, and consolidation therapy with VTd alone or in combination with DARZALEX®.7 The primary endpoint in this part of the study is the proportion of patients who achieve a sCR at the end of consolidation therapy.8
The most frequently reported treatment emergent adverse events (≥20 per cent) in the DVTd arm were: infusion-related reactions, peripheral sensory neuropathy, constipation, asthenia, upper respiratory tract infections, nausea, peripheral edema, neutropenia, pyrexia, paraesthesia, and thrombocytopenia. Serious adverse events with a 2 per cent higher incidence in the DVTd arm compared to the VTd arm included neutropenia (DVTd 3.9 per cent vs. VTd 1.5 per cent) and pneumonia (DVTd 3.5 per cent vs. VTd 1.7 per cent).9
In the second part of the study, which is ongoing, patients who achieved a partial response or better in part one underwent a second randomization to receive maintenance treatment with DARZALEX® 16 mg/kg every eight weeks for up to two years or be observed with no further treatment. The primary endpoint in the second part of the study is PFS. 10
About DARZALEX®
DARZALEX® is the first CD38-directed monoclonal antibody approved to treat multiple myeloma. In 2020, the subcutaneous formulation, DARZALEX® SC, was approved by Health Canada to treat patients with multiple myeloma.11
DARZALEX® binds to CD38, a surface protein highly expressed across multiple myeloma cells.12 DARZALEX® induces tumor cell death through cell lysis via multiple immune-mediated mechanisms of action, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).13 DARZALEX® has also demonstrated immunomodulatory effects such as increasing CD4+ and CD8+ T-cells counts, which may contribute to clinical response.14
In August 2012, Janssen Biotech, Inc. and Genmab A/S entered a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize DARZALEX®. Janssen Inc. commercializes DARZALEX® and DARZALEX® SC in Canada. For full Prescribing Information and more information about DARZALEX® and DARZALEX®SC, please visit www.janssen.com/canada.
About Multiple Myeloma
Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.15 When damaged, these plasma cells rapidly spread and replace normal cells with tumors in the bone marrow. In 2020, it is estimated that 3,400 Canadians will be diagnosed with multiple myeloma and there will be 1,600 deaths associated with the disease.16 While some patients with multiple myeloma have no symptoms in the early stages, patients are diagnosed due to symptoms that can include bone disease or pain, anemia, calcium elevation, and kidney problems.17
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.
Learn more at www.janssen.com/canada. Follow us at @JanssenCanada. Janssen Inc. and Janssen Research & Development, LLC are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
*All trademark rights used under license.
**Dr. LeBlanc was not compensated for any media work. He has been compensated as a consultant.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding DARZALEX®. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Inc., any of the other Janssen Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 29, 2019, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
References:
1 DARZALEX® Product Monograph, Janssen Inc., Nov 17, 2020
2 DARZALEX® Product Monograph, Janssen Inc., Nov. 17, 2020
3 DARZALEX® Product Monograph, Janssen Inc., Nov. 17, 2020
4 DARZALEX® Product Monograph, Janssen Inc., Nov. 17, 2020
5 Moreau, P et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. The Lancet. 2019; 394: 29–38.
6 DARZALEX® Product Monograph, Janssen Inc., Nov. 17, 2020
7 DARZALEX® Product Monograph, Janssen Inc., Nov. 17, 2020
8 DARZALEX® Product Monograph, Janssen Inc., Nov. 17, 2020
9 DARZALEX® Product Monograph, Janssen Inc., Nov. 17, 2020
10 Moreau, P et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. The Lancet. 2019; 394: 29–38.
11 Janssen Research & Development, LLC. A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 [cited July 5, 2019]. Available at: https://clinicaltrials.gov/ct2/show/NCT03412565. Identifier: NCT03412565.
12 DARZALEX® Product Monograph, Janssen Inc., Nov. 17, 2020
13 DARZALEX® Product Monograph, Janssen Inc., Nov. 17, 2020
14 DARZALEX® Product Monograph, Janssen Inc., Nov. 17, 2020
15 Kumar, SK et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan; 26(1):149-57.
16 Canadian Cancer Society. "Signs and Symptoms of Multiple Myeloma." Available at: https://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/statistics/?region=on. Accessed November 2020.
17 Canadian Cancer Society. "Signs and Symptoms of Multiple Myeloma." Available at: http://www.cancer.ca/en/cancer-information/cancer-type/multiple-myeloma/signs-and-symptoms/?region=on. Accessed November 2020.
SOURCE Janssen Inc.
Sign Up and get a free 7 day Train it Right HIIT Program!